10 Best Stocks to Buy and Hold For 2025

3. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Average Price Target Upside Potential According to Analysts: 66.17%

Number of Hedge Fund Holders: 62

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is an American biotechnology company that is primarily focused on discovering, developing, and commercializing medicines for serious diseases. The company currently has 13 approved or authorized medicines and about 40 product candidates in clinical development across various therapeutic areas. Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) medicines and pipeline are focused on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular diseases, neurological diseases, hematologic conditions, and rare diseases.

The company is making significant progress with its products and pipeline. In September 2024, the US Food and Drug Administration (FDA) approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, making it the first biologic medicine approved in the US, European Union, and China for this condition. According to Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), more than one million patients around the world are being treated with Dupixent, with more to follow after the recent approvals for COPD.

Baron Funds, an investment management company, in its “Baron Health Care Fund” third quarter 2024 investor letter noted the success of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in developing several blockbuster drugs, including Eylea and Eylea HD for retinal diseases and Dupixent for various immunological and inflammatory diseases. Additionally, the company has an exciting new product pipeline with candidates in different stages of development. The pipeline includes an innovative treatment for severe food allergy, a combination therapy for melanoma and lung cancer, bispecific antibodies for blood cancers, and Factor XI antibodies for preventing blood clots. Based on Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) proven track record of success in new drug discovery and development, Baron Health Care Fund is optimistic that the pipeline will yield success that could drive the stock up.